REG - Theracryf PLC - Notice of Results

TheracryfAnnouncement

14/11/2024 11:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241114:nRSN2795Ma&default-theme=true

RNS Number : 2795M  Theracryf PLC  14 November 2024

TheraCryf plc

("TheraCryf", the "Company" or the "Group")

 

Notice of Interim results and Presentation via Investor Meet Company

 

Alderley Park, 14 November 2024 - TheraCryf plc (AIM: TCF), formerly Evgen
Pharma plc, the clinical stage drug development company focussing on oncology
and neuropsychiatry, announces that the Company's unaudited interim results
for the six months to 30 September 2024 will be released on Thursday 28
November 2024.

 

The results will be available via the London Stock Exchange's Regulatory News
Service (RNS) and on the Investor Relations section of the Company's website:
www.theracryf.com/investors (http://www.theracryf.com/investors) .

 

Huw Jones, CEO, and Toni Hänninen, CFO will provide a live presentation via
the Investor Meet Company platform at 11am on Thursday 28 November 2024.

 

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via the Investor Meet Company dashboard up until 27
November 2024, 09:00 GMT, or at any time during the live presentation.
Investors who already follow TheraCryf plc on the Investor Meet Company
platform will automatically be invited.

 

Investors can sign up to Investor Meet Company HERE
(https://www.investormeetcompany.com/theracryf-plc/register-investor) .

 

-Ends-

Enquiries

 TheraCryf plc                                               +44 (0)1625 315 090

Dr Huw Jones, CEO
enquiries@theracryf.com

Toni Hänninen, CFO

Dr Helen Kuhlman, CBO
 Cavendish Capital Markets (NOMAD and Broker)                +44 (0)20 7220 0500
 Geoff Nash / Teddy Whiley / Rory Sale (Corporate Finance)

Nigel Birks / Harriet Ward (ECM)
 Vigo Consulting                                             +44 (0)20 7390 0231
 Rozi Morris
theracryf@vigoconsulting.com

 

About TheraCryf plc

TheraCryf is the clinical stage drug development company focussing on oncology
and neuropsychiatry. The Company has a broad clinical and preclinical pipeline
in indications including glioblastoma* neurodevelopmental disorders,
addiction, anxiety and narcolepsy [*orphan indication].

The Company's strategy is to generate compelling data sets to preclinical
and/or clinical proof of concept and partner its clinical programmes with
mid-size to large pharma for larger trials and commercialisation. As well as a
number of industry partnerships with companies, including Stalicla SA, in
neurodevelopmental disorders. The Company has sourced know how for programmes
from companies such as Shire (now Takeda).

TheraCryf has worked with and has ongoing collaborations with major
universities and hospitals such as the University of Manchester, La Sapienza
(Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College
London and the University of Michigan.

The Company has its headquarters and registered office at Alderley
Park, Cheshire. It is quoted on AIM in London and trades under the ticker
symbol TCF. 

For further information, please visit: www.theracryf.com
(http://www.theracryf.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORBIBMTMTBBBFI